Related Experiment Video

Updated: Jun 3, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Treatment of congenital heart disease: risk-reducing measures in young adults

Teun van der Bom1, Paul Luijendijk, Berto J Bouma

  • 1Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Future Cardiology
|April 2, 2011
PubMed

Insights

Adults with congenital heart disease (ACHD) face frequent late complications and heart failure. Recent advances focus on pharmacological, interventional, and surgical treatments to improve long-term survival and reduce risks in this growing population.

Area of Science:

  • Cardiology
  • Adult Congenital Heart Disease (ACHD)

Background:

  • Adults with congenital heart disease (ACHD) represent a growing population due to improved surgical survival.
  • Long-term survival data for ACHD patients are limited, with frequent late complications impacting quality of life.

Purpose of the Study:

  • To review recent advances in managing adults with congenital heart disease.
  • To focus on interventions reducing the risk of major complications and mortality.

Main Methods:

  • Review of current pharmacological treatments for ACHD.
  • Discussion of interventional cardiology techniques for ACHD.
  • Analysis of surgical strategies in adult congenital heart disease management.

Main Results:

  • Late complications in ACHD include endocarditis, stroke, hypertension, aortic issues, and arrhythmias.
  • Heart failure and sudden cardiac death are primary causes of mortality in ACHD.
  • Treatment aims to alleviate symptoms and mitigate risks of severe late complications.

Conclusions:

  • Effective management of ACHD requires addressing late complications and reducing mortality risks.
  • Pharmacological, interventional, and surgical advances are crucial for improving outcomes in adults with congenital heart disease.

More Related Videos

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods08:28

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods

Published on: March 10, 2020

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents06:33

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents

Published on: September 21, 2021

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...